Exelixis Inc
Change company Symbol lookup
Select an option...
EXEL Exelixis Inc
MDIA Mediaco Holding Inc
SWVLW Swvl Holdings Equity Warrant Exp 31st Mar 2027 *W EXP 03/31/2027
SCBCX Franklin Multi-Asset Conservative Growth Fund C
BUI BlackRock Utilities, Infrastructure & Power Opportunities Trust
FDEU First Trust Dynamic Europe Equity Income
DOCU DocuSign Inc
DHCAU DHC Acquisition Corp
BCH Banco de Chile
NLRCF Northern Lights Resources Corp
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Premarket

Last Trade
Delayed
$21.64
0.07 (0.32%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$21.57
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
36

10-day average volume:
3,276,998
36

Company Profile

Exelixis, Inc. is an oncology focused biotechnology company. The Company is engaged in the discovery, development, and commercialization of medicines to treat cancers. Its cabozantinib molecule, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. Cabozantinib is approved as CABOMETYX tablets used for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company's (BMS) OPDIVO (nivolumab), for hepatocellular carcinoma (HCC) and for radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). Cabozantinib is also approved as COMETRIQ capsules for metastatic medullary thyroid cancer (MTC). Its other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Valuation Ratios

Price/Earnings (TTM)
23.38x
Price/Sales (TTM)
4.55x
Price/Book (MRQ)
3.01x
Price/Cash Flow (TTM)
22.11x
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

June 2022
Current Month
12.0M
Previous Month
10.9M
Percent of Float
3.82%
Days to Cover
5.1545 Days

Share Information

EXEL is in a share class of common stock
Float
314.4M
Shares Outstanding
320.7M
Institutions Holding Shares
494
85.77%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Stelios B. Papadopoulos
  • Michael M. MorrisseyCEO
  • Christopher J. SennerCFO
  • Peter LambExec.VP
  • Jeffrey J. HessekielExec.VP

Address

Insider Trading

During the most recent quarter, 339K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.